MAOB and Parkinson disease: In 2009, Petzer et al. suggested that simultaneous targeting of the dopamine-metabolizing, H2O2-producing enzyme monoamine oxidase B (MAO-B) by inhibitors, and of A2A ARs by antagonists, may be advantageous for the treatment of PD due to their dopamine-enhancing effects.